|Articles|January 24, 2022

Most COVID-19 Patients Admitted to ICU Still Experience Symptoms 1 Year Later

Author(s)Nina Cosdon

Nearly 75% of COVID-19 patients admitted to the ICU were symptomatic 1 year later, most commonly reporting weakened condition and musculoskeletal problems.

The COVID-19 pandemic caused many patients to fall critically ill and require treatment in an intensive care unit (ICU). Even a year later, the ICU patients who survived COVID-19 commonly experience physical, mental, and cognitive symptoms.

The exploratory prospective multicenter cohort study was conducted in the ICUs of 11 Dutch hospitals and published today in the Journal of the American Medical Association (JAMA). Investigators included 452 patients aged 16 and older who survived ICU admission during the first COVID-19 surge (March 1-July 1, 2020). The patients were followed up for 1 year following their release from the ICU, and the final follow-up date was June 16, 2021.

The main outcomes were physical symptoms (including frailty, fatigue, and other physical problems), mental symptoms (anxiety, depression, PTSD), and cognitive symptoms self-reported 1 year after ICU treatment.

Of the initial patient cohort, 301 (66.8%) were included in the study. The average age was 61.2 years, the average duration of ICU stay was 18 days, and 71.5% were male. A year after their release from the ICU, 74.3% of patients reported physical symptoms, 26.2% reported mental symptoms, and 16.2% reported cognitive symptoms.

The most commonly reported new physical problems were weakened condition (38.9%), joint stiffness (26.3%), joint pain (25.5%), muscle weakness (24.8%), and myalgia (21.3%).

The respondents indicated that their continued COVID-19 symptoms make it difficult to go about their day-to-day lives, with 58% of ICU survivors saying they had problems returning to work.

This frequency of symptoms 1 year after recovering from severe COVID-19 disease is concerning, as much is still unknown about “long covid” and the long-term health impact of COVID-19 infection.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.